Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 2/2016

01-08-2016

Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC–MS/MS method

Authors: Wan-li Zhang, Dan Lou, Dong-tao Zhang, Yin Zhang, Huan-jie Huang

Published in: Journal of Thrombosis and Thrombolysis | Issue 2/2016

Login to get access

Abstract

To establish a rapid and sensitive ultra performance liquid chromatography tandem mass spectrometry (UPLC–MS/MS) method for the determination of rivaroxaban, apixaban and edoxaban in rat plasma. The analytes and the internal standard (diazepam) were separated on an Acquity UPLC BEH C18 chromatography column (2.1 mm × 50 mm, 1.7 μm) using gradient elution with a mobile phase of acetonitrile and 0.1 % formic acid in water at a flow rate of 0.4 mL/min. The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring mode to monitor the precursor-to-product ion transitions of m/z 436.1 → 145.1 for rivaroxaban, m/z 460.0 → 443.1 for apixaban, m/z 548.2 → 366.1 for edoxaban and m/z 285.2 → 193.1 for diazepam (IS) using a positive electrospray ionization interface. The method was validated over a concentration range of 1.0–200 ng/mL for rivaroxaban, 1.0–100 ng/mL for apixaban and 1.0–500 ng/mL for edoxaban. Total time for each chromatograph was 3.5 min. The intra- and inter-day precision and accuracy of the quality control samples at low, medium, and high concentration levels exhibited relative standard deviations <10.5 % and the accuracy values ranged from −9.9 to 11.3 %. The method was successfully applied to a pharmacokinetic study of rivaroxaban, apixaban and edoxaban in rats.
Literature
1.
go back to reference Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F (2011) The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov 10:61–75CrossRefPubMed Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F (2011) The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov 10:61–75CrossRefPubMed
2.
5.
go back to reference Mendell J, Tachibana M, Shi M, Kunitada S (2011) Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol 51:687–694CrossRefPubMed Mendell J, Tachibana M, Shi M, Kunitada S (2011) Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol 51:687–694CrossRefPubMed
6.
go back to reference Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R et al (2013) Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 75:476–487CrossRefPubMed Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R et al (2013) Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 75:476–487CrossRefPubMed
7.
go back to reference Stampfuss J, Kubitza D, Becka M, Mueck W (2013) The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther 51:549–561CrossRefPubMed Stampfuss J, Kubitza D, Becka M, Mueck W (2013) The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther 51:549–561CrossRefPubMed
8.
go back to reference Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G et al (2012) Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e44S–e88SCrossRefPubMedPubMedCentral Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G et al (2012) Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e44S–e88SCrossRefPubMedPubMedCentral
9.
go back to reference Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:2719–2747CrossRefPubMed Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:2719–2747CrossRefPubMed
10.
go back to reference Samama MM, Guinet C (2011) Laboratory assessment of new anticoagulants. Clin Chem Lab Med 49:761–772CrossRefPubMed Samama MM, Guinet C (2011) Laboratory assessment of new anticoagulants. Clin Chem Lab Med 49:761–772CrossRefPubMed
11.
go back to reference Barrett YC, Wang Z, Knabb RM (2013) A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors. Clin Appl Thromb/Hemost 19:522–528CrossRef Barrett YC, Wang Z, Knabb RM (2013) A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors. Clin Appl Thromb/Hemost 19:522–528CrossRef
12.
go back to reference Schmitz EM, Boonen K, van den Heuvel DJ, van Dongen JL, Schellings MW, Emmen JM et al (2014) Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography: tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J Thromb Haemost 12:1636–1646CrossRefPubMed Schmitz EM, Boonen K, van den Heuvel DJ, van Dongen JL, Schellings MW, Emmen JM et al (2014) Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography: tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J Thromb Haemost 12:1636–1646CrossRefPubMed
13.
go back to reference Korostelev M, Bihan K, Ferreol L, Tissot N, Hulot JS, Funck-Brentano C et al (2014) Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 100:230–235CrossRefPubMed Korostelev M, Bihan K, Ferreol L, Tissot N, Hulot JS, Funck-Brentano C et al (2014) Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 100:230–235CrossRefPubMed
14.
go back to reference Iqbal M, Khalil NY, Imam F, Khalid Anwer M (2015) A validated high-throughput UHPLC-MS/MS assay for accurate determination of rivaroxaban in plasma sample. J Thromb Thrombolysis 39:79–88CrossRefPubMed Iqbal M, Khalil NY, Imam F, Khalid Anwer M (2015) A validated high-throughput UHPLC-MS/MS assay for accurate determination of rivaroxaban in plasma sample. J Thromb Thrombolysis 39:79–88CrossRefPubMed
15.
go back to reference Rohde G (2008) Determination of rivaroxaban–a novel, oral, direct Factor Xa inhibitor–in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B 872:43–50CrossRef Rohde G (2008) Determination of rivaroxaban–a novel, oral, direct Factor Xa inhibitor–in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B 872:43–50CrossRef
16.
go back to reference Pursley J, Shen JX, Schuster A, Dang OT, Lehman J, Buonarati MH et al (2014) LC-MS/MS determination of apixaban (BMS-562247) and its major metabolite in human plasma: an application of polarity switching and monolithic HPLC column. Bioanalysis 6:2071–2082CrossRefPubMed Pursley J, Shen JX, Schuster A, Dang OT, Lehman J, Buonarati MH et al (2014) LC-MS/MS determination of apixaban (BMS-562247) and its major metabolite in human plasma: an application of polarity switching and monolithic HPLC column. Bioanalysis 6:2071–2082CrossRefPubMed
17.
go back to reference Delavenne X, Mismetti P, Basset T (2013) Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study. J Pharm Biomed Anal 78–79:150–153CrossRefPubMed Delavenne X, Mismetti P, Basset T (2013) Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study. J Pharm Biomed Anal 78–79:150–153CrossRefPubMed
18.
go back to reference Zheng N, Yuan L, Ji QC, Mangus H, Song Y, Frost C et al (2015) “Center punch” and “whole spot” bioanalysis of apixaban in human dried blood spot samples by UHPLC-MS/MS. J Chromatogr B 988:66–74CrossRef Zheng N, Yuan L, Ji QC, Mangus H, Song Y, Frost C et al (2015) “Center punch” and “whole spot” bioanalysis of apixaban in human dried blood spot samples by UHPLC-MS/MS. J Chromatogr B 988:66–74CrossRef
19.
go back to reference Gous T, Couchman L, Patel JP, Paradzai C, Arya R, Flanagan RJ (2014) Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry. Ther Drug Monit 36:597–605CrossRefPubMed Gous T, Couchman L, Patel JP, Paradzai C, Arya R, Flanagan RJ (2014) Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry. Ther Drug Monit 36:597–605CrossRefPubMed
20.
go back to reference Qiu X, Wang Z, Wang B, Zhan H, Pan X, Xu RA (2014) Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma by ultra high performance liquid chromatography tandem mass spectrometry and its application to a bioequivalence study. J Chromatogr B 957:110–115CrossRef Qiu X, Wang Z, Wang B, Zhan H, Pan X, Xu RA (2014) Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma by ultra high performance liquid chromatography tandem mass spectrometry and its application to a bioequivalence study. J Chromatogr B 957:110–115CrossRef
21.
go back to reference Qiu X, Zhao JL, Hao C, Yuan C, Tian N, Xu ZS et al (2016) Simultaneous determination of mangiferin and neomangiferin in rat plasma by UPLC-MS/MS and its application for pharmacokinetic study. J Pharm Biomed Anal 124:138–142CrossRefPubMed Qiu X, Zhao JL, Hao C, Yuan C, Tian N, Xu ZS et al (2016) Simultaneous determination of mangiferin and neomangiferin in rat plasma by UPLC-MS/MS and its application for pharmacokinetic study. J Pharm Biomed Anal 124:138–142CrossRefPubMed
Metadata
Title
Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC–MS/MS method
Authors
Wan-li Zhang
Dan Lou
Dong-tao Zhang
Yin Zhang
Huan-jie Huang
Publication date
01-08-2016
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 2/2016
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-016-1367-y

Other articles of this Issue 2/2016

Journal of Thrombosis and Thrombolysis 2/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.